Loading...

StageZero Life Sciences Ltd.

SZLSFPNK
Healthcare
Medical - Diagnostics & Research
$0.02
$0.005(30.000%)

StageZero Life Sciences Ltd. (SZLSF) Company Profile & Overview

Explore StageZero Life Sciences Ltd.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

StageZero Life Sciences Ltd. (SZLSF) Company Profile & Overview

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.

SectorHealthcare
IndustryMedical - Diagnostics & Research
CEOJames R. Howard-Tripp

Contact Information

70 East Beaver Creek Road, Richmond Hill, ON, L4B 3B2

Company Facts

40 Employees
IPO DateSep 8, 2009
CountryCA
Actively Trading

Frequently Asked Questions

;